Metrifonate (Trichlorfon): a review of the pharmacology, pharmacokinetics and clinical experience with a new acetylcholinesterase inhibitor for Alzheimer’s disease

By Cummings J.L.   Ringman J.M.  

Expert Opinion on Investigational Drugs, Vol. 8, Iss. 4, 1999-04 ,pp. : 463-471

Informa Healthcare

Access to resources Recommend Favorite

The pharmacology of donepezil: a new treatment for Alzheimer’s disease

By Wilkinson D.G.  

Expert Opinion on Pharmacotherapy, Vol. 1, Iss. 1, 1999-11 ,pp. : 121-135

Informa Healthcare

Access to resources Recommend Favorite

Clinical benefits are maintained during long-term treatment of Alzheimer's disease with the acetylcholinesterase inhibitor, E2020

By Rogers S.L.   Perdomo C.   Friedhoff L.T.  

European Neuropsychopharmacology, Vol. 5, Iss. 3, 1995-09 ,pp. : 386-387

Elsevier

Access to resources Recommend Favorite

A Review of Clinical Pharmacokinetics and Pharmacodynamics of Galantamine, a Reversible Acetylcholinesterase Inhibitor for the Treatment of Alzheimer 's Disease, in Healthy Subjects and Patients

By  

Current Clinical Pharmacology, Vol. 5, Iss. 2, 2010-05 ,pp. : 115-124

Bentham Science Publishers

Access to resources Recommend Favorite

Inhibitory effect of orally administered donepezil hydrochloride (E2020), a novel treatment for Alzheimer's disease, on cholinesterase activity in rats

By Kosasa T.   Kuriya Y.   Matsui K.   Yamanishi Y.  

European Journal of Pharmacology, Vol. 389, Iss. 2, 2000-02 ,pp. : 173-179

Elsevier

Access to resources Recommend Favorite